ELRANATAMAB

UNII:	L0HR9A577V
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	ELRANATAMAB
GSRS Full Record:	L0HR9A577V i

2408850-14-4
ANTI-CD3/ANTI-BCMA BISPECIFIC MONOCLONAL ANTIBODY PF-06863135
B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
ELRANATAMAB [USAN]
ELREXFIO
Elranatamab
Elranatamab [MI]
Elranatamab [WHO-DD]
Elranatamab bcmm [WHO-DD]
Elranatamab-BCMM
Immunoglobulin G2 [224-arginine,265-alanine,330-serine,331-serine], anti-(human CD3 antigen ε-chain) (human-Mus musculus monoclonal PF-06863059 γ2-chain), disulfide with human-Mus musculus monoclonal PF-06863059 κ-chain, (223→217′)(227→221′)(230→224′)-tris(disulfide) with immunoglobulin G2 [218-glutamic acid,259-alanine,324-serine,325-serine] anti-(human B-cell maturation antigen) (human monoclonal PF-06863058 γ2-chain) disulfide with human monoclonal PF-06863058 κ-chain
Immunoglobulin G2-kappa, anti-(Homo sapiens T-cell surface glycoprotein CD3 epsilon chain CD3E (T-cell surface antigen T3/Leu-4 epsilon chain)), human-Mus musculus monoclonal disulfide with immunoglobulin G2-kappa, anti-(Homo sapiens - Tumor necrosis factor receptor superfamily member 17 TNR17 (B-cell maturation protein; CD269_antigen)), human-Mus musculus monoclonal disulfide with immunoglobulin G2-kappa. γ2 heavy chain antiCD3E (1-447) [Homo sapiens VH (IGHV3-48*03 (84%) –(IGHD)-IGHJ4*01 (86%)) [8.10.12] (1-121) -Homo sapiens IGHG2*01 {hinge[C5>R(224),E7>R(226),P10>R(229)], CH2[D35>A(265), A100>S(330),P101>S(331)], CH3[K69>R(409)]} (122-447)] (135-219')-disulfide with κ light chain anti-CD3E (1'-219') [V-KAPPA (Homo sapiens IGKV4-1*01 (90%)-IGKJ2*02 (91%)/Mus musculus IGKV8-21*01 (84%)-IGKJ4*01) [12.3.8] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; (223-217'':227-221'':230-224'')-trisdisulfide with γ2 heavy chain anti-TNR17 (1''-441'') [Homo sapiens VH (IGHV3-23*01 (94%) –(IGHD)-IGHJ1*01) [8.8.8] (1''-115'') -Homo sapiens IGHG2*01 {hinge[C5>E(218''),P10>E(223'')], CH2[D35>A(259''),A100>S(324''),P101>S(325'')], CH3[L28>E(362'')]} (116''-441'') (129''-215''')-disulfide with κ light chain anti-TNR17 (1'''-215''') [Homo sapiens V-KAPPA (Homo sapiens IGKV3-20*01 (95%) –IGKJ1*01)[7.3.9] (1'''-108''') -Homo sapiens IGKC*01 (109'''-215''')
PF-06863135
RN-613
RN613
elranatamab [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

ELRANATAMAB

Synonyms and Mappings

Resources